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Abstract: The methylation of histone lysine residues modifies chromatin conformation and regulates
the expression of genes implicated in cell metabolism. Lysine-specific demethylase 1 (LSD1) is a
flavin-dependent monoamine oxidase that can demethylate mono- and dimethylated histone lysines
4 and 9 (H3K4 and H3K9). The removal of methyl groups from the lysine residues of histone and
non-histone proteins was found to be an important regulatory factor of cell proliferation. However,
its role has not been fully elucidated. In this study, we assessed LSD1-mediated cell cycle progression
using a human endothelial cell model. The short hairpin RNA knockdown of LSD1 inhibits the G2/M
phase of cell cycle progression by checkpoint kinase 1 (Chk1) phosphorylation (S137). We observed
elevated DNA damage, which was consistent with the increased detection of double-strand breaks
as well as purines and pyrimidines oxidation, which accompanied the activation of ATR/ATRIP
signaling by H2AXS139 phosphorylation. The irreversible pharmacological inhibition of LSD1 by
2-phenylcyclopropylamine (2-PCPA) inactivated its enzymatic activity, causing significant changes in
heterochromatin and euchromatin conformation assessed by chromatin assembly factor 1 subunit A
(CAF1A) and heterochromatin protein 1 isoform α and γ (HP1α/γ) immunofluorescence analysis. We
conclude that the knockdown of LSD1 in endothelial cells leads to increased HP1-positive chromatin,
the stimulation of DNA repair processes, and the dysregulation of proliferation machinery.
Keywords: LSD1; histone posttranslational modifications; cell cycle; Chk1; chromatin remodeling;
DNA damage and repair
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1. Introduction
Recent studies in transcriptional biology have highlighted the importance of epigenetic
determinants in the regulation of cell metabolism. One of the main components of the regulatory
machinery is the modulation of the demethylation of histone proteins by lysine-specific demethylase 1,
LSD1 (also known as KDM1A, AOF2, and BHC110) [1]. LSD1 was the first of several protein lysine
demethylases discovered [2], and to date, it is one of the most studied enzymes responsible for the
demethylation of mono- and dimethylated lysines at position 4 or 9 in histone H3 (H3K4 and H3K9,
respectively). The structure of LSD1 classifies the enzyme as a member of the monoamine oxidase
(MAO) superfamily, and is highly conserved among many species, ranging from Schizosaccharomyces
pombe to human [3–5].
The complexity of the demethylation process catalyzed by LSD1 depends on the interaction of the
enzyme with specific chromatin regulatory complexes, including RE1-silencing transcription factor
(REST), co-repressor CoREST (co-repressor for element 1-silencing transcription factor), nucleosome
remodeling and histone deacetylation (NuRD), and SNAIL/Slug, or RCOR2 [6–10]. The broad
consequences of demethylation controlled by LSD1 explain the substrate specificity of the lysine-specific
demethylase containing histones as well as many crucial non-histone proteins, especially transcription
factors (i.e., E2f1), chromatin-regulating proteins (i.e., Dnmt1), and also tumor suppressor proteins
(i.e., p53) [11–13]. Additionally, the switching activity of LSD1 from a repressor function to that
of a co-activator seems to be therapeutically attractive, and a major component in epigenetic
reprogramming, as well as in the regulation of the cell cycle, which depends on a highly regulated
series of converging signals including transcription factors, non-coding RNAs, DNA methylation, and
histone modifications [14–16].
Recent findings provide more and more details into the epigenetic machinery picture that
controls cell proliferation and survival [17–19]; nevertheless, the chromatin remodeling process that is
important for cell cycle regulation and DNA damage response remain still incompletely understood.
The interaction of co-activators and co-repressors with LSD1 plays a significant role in altering chromatin
structure through the modification of core histone amino acid tails [20,21]. It was found that LSD1 is
recruited to the chromatin of cells at G1/S/G2 phases [22], and its genetic ablation in embryonic stem
cells (ESCs) results in the impaired differentiation properties of cells, apoptosis induction, and failure
in maintaining global DNA methylation [12,23]. Conversely, a high overexpression of LSD1 in many
solid tumors possessing aggressive clinicopathological features, i.e., neuroblastoma, chondrosarcoma,
or hepatocellular carcinoma, suggests that the enzyme can serve as an oncogene in the context of
malignant transformation [24–26].
Most of the studies characterizing the role of LSD1 in metabolism is related with cancer biology,
and little is known about the role of LSD1 in endothelial cell proliferation, which is crucial for circulatory
functions as well as for cancer progression and metastasis. In this article, we examine the role of
lysine-specific demethylase 1 (LSD1) in the control of endothelial cell cycle, using (i) pharmacological and
(ii) transcriptional models of inactivation of the enzyme activity (2-PCPA-treated human microvascular
endothelial cells-1/human umbilical vein endothelial cells (HMEC-1/HUVECs) and pTRIPZ shRNA
vector transfected HMEC-1, respectively). The studies performed on immortalized (HMEC-1) as
well as primary cells (HUVECs) showed that LSD1 efficiently affects endothelial cells proliferation,
presumably via Chk1, and involves the ATR/ATRIP signaling pathway, as a result of promoting the
transient formation of repressive chromatin.
2. Materials and Methods
2.1. Cell Culture and Chemical Inhibitor Description
HMEC-1 (human microvascular endothelial cells-1) were obtained from the Center for Disease
Control and Prevention, Emory University (Atlanta, GA, USA). Cells were cultured in MCDB 131
medium (Life Technologies, Carlsbad, California, USA) containing 10 ng/mL of epidermal growth
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factor (Millipore, Burlington, MA, USA), 10 mM glutamine (Invitrogen; Carlsbad, CA, USA), and 10%
heat-inactivated fetal bovine serum (Life Technologies, Carlsbad, CA, USA). For HUVECs (human
umbilical vein endothelial cells), the same cell culture conditions were applied. Cells were isolated
form veins of freshly collected umbilical cords, by collagenase type II digestion, according to Jaffe’s
protocol [27], and used for the experiments at passage 3-4. A permission for HUVEC’s isolation was
obtained from the Bioethical Commission at Medical University of Lodz (decision no. RNN/264/15/KE).
2-PCPA, tranylcypromine hydrochloride, was purchased from Cayman Chemicals (Ann Arbor,
MI, USA). 2-PCPA is an irreversible, mechanism-based inhibitor of LSD1 with an IC50 value of 20.7 µM
and a Ki value of 242.7 µM that effectively inhibits histone demethylation in vivo. Although not as
selective, 2-PCPA also irreversibly inhibits monoamine oxidase (MAO) type A and type B with IC50
values of 2.3 and 0.95 µM and Ki values of 101.9 and 16 µM, respectively [28,29].
2.2. shRNA Silencing of Lysine-Specific Histone Demethylase 1 (LSD1) Activity
The silencing of lysine demethylase-1 was performed in HMEC-1 using an inducible system
for LSD1 knockdown (LSD1 KD) by shRNA (mature antisense sequence: 5′-GGAAAGAATCAAGG
AGG-3′; Clone ID: V3THS_361041; Dharmacon; Lafayette, CO, USA). As a control for LSD1 DMT
silencing, cells transduced with an empty vector were used: nonTarget (nonT; #RHS4743; Dharmacon;
Lafayette, CO, USA). shRNA vector amplification in 293FT cells and the subsequent transduction of
HMEC-1 was performed according to the manufacturer’s protocol. Upon the addition of 1 µg/mL
doxycycline (DOX) to HMEC-1, to induce LSD1 silencing, expression of the targeted gene was
downregulated by >70%, as measured by quantitative PCR. Changes in the expression of demethylase
were also estimated by Western blotting at the protein level.
2.3. Immunocytochemistry
Immunocytochemical detection of both total and phosphorylated form of Chk1 was performed
using rabbit polyclonal antibodies purchased from Abcam (Cambridge, UK) and Cell Signaling
Technology (Danvers, MA, USA), respectively. Rabbit polyclonal antibodies specific to HP-1α and
HP-1γ proteins were purchased from Abcam (Cambridge, UK). Rabbit polyclonal antibodies specific
both to phospho-H2AX (i.e., H2AXS139ph) and ATRIP, rabbit monoclonal antibodies specific to
CAF1A, as well as mouse monoclonal antibodies specific to PCNA were purchased from Cell Signaling
Technology (Danvers, MA, USA). Bound primary antibodies were detected with secondary goat
anti-rabbit Alexa Fluor 488-labeled antibody (Cell Signaling Technology, Danvers, MA, USA).
HMEC-1 were grown in 8-well tissue culture plates containing sterile coverslips, and were treated
as indicated in the figure legends. For the immunocytochemical detection of total Chk1, phospho-Chk1
(Chk1S317ph), phospho-H2AX (H2AXS139ph), PCNA, ATRIP, HP-1α, and HP-1γ, cells were fixed for
45 min in 4% paraformaldehyde (PFA) buffered with phosphate-buffered saline (PBS), as previously
described [18]. The cells were pre-treated in a blocking buffer (10% horse serum, 1% bovine serum
albumin (BSA), 0.02% NaN3, 1× PBS) for 1 h at room temperature to minimize the non-specific
adsorption of antibodies to the coverslips, and subsequently were incubated overnight at 4 ◦C with
primary antibodies (1:750). Cells were washed three times (5 min each) with PBS/0.2% Triton X-100
(PBT) prior to incubation with secondary antibodies (1:1000) for 1 h at 37 ◦C in the dark. Next,
cells were washed three times with PBT (5 min each), and then for 5 min in PBS. Coverslips were
covered by cover glass under 4 µL of Vectashield mounting medium (Vector Laboratories) containing
4′,6-diamidyno-2-fenyloindol (DAPI; for Chk1 total, Chk1S317ph, PCNA, ATRIP, CHAF1A, HP1α
and HP-1γ staining) or propidium iodide (PI; for H2AXS139ph staining). Observations were made
using an AxioImager A1 fluorescence microscope (Zeiss, Jena, Germany) equipped with cyanine 3
(Cy3), green fluorescent protein (GFP), and DAPI filters. Negative control sections incubated with
non-immune serum in the place of primary antibodies were free from immunostaining (data not
shown); these negative control sections gave bright propidium iodide or DAPI signals, but completely
lacked fluorescence in the wavelength of Alexa Fluor 488-conjugated secondary antibodies. Image
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data were collected at exactly the same exposure time on an AxioCam MRc5 CCD camera (Zeiss,
Jena, Germany).
Data collection for cell cycle analysis: The quantification of aberrant mitoses (M-phase cells) was
determined by counterstaining with DAPI (0.1 mg/mL; 4’,6-diamidino-2-phenylindole; Sigma-Aldrich,
Saint Quentin, France) for 5 min at room temperature. The aberrant M-phase cells were observed
using a fluorescence microscope equipped with UV-2A filter (UV-light; λ = 518 nm). All images were
recorded at exactly the same time of integration with an AxioCam MRc5 CCD camera (Zeiss, Jena,
Germany). The mitotic index was calculated as the percent ratio between the number of dividing
cells and the entire HMEC-1 cell population. An index of aberrations (M-phase aberrant cells) was
calculated as the percent ratio between the number of cells showing chromosome aberrations and all
mitotic HMEC-1 cells. The apoptotic index was calculated as the percent ratio between the number of
apoptotic cells and the entire HMEC-1 cell population.
2.4. Cell Cycle Analysis by FACS
Cell preparation: Cells were seeded onto the 6-cm dishes (NUNC™, Thermo Scientific™, Denmark)
at a density of 40,000. After the incubation of cells with 2-PCPA or DOX (shRNA transfected cells) the
medium was removed; then, cells were washed twice in PBS, trypsinized, washed twice in PBS, and
centrifuged (3000 rpm, 3 min). After that, cells were fixed in 70% ethanol for 24 h at 4 ◦C. In the next
step, the cell solution was centrifuged (10,000 rpm, 7 min), and the pellet was resuspended in PBS.
Before analysis, cells were incubated for 30 min at 37 ◦C in the buffer containing RNase A (0.1 mg/mL;
Sigma-Aldrich, St. Louis, MO, USA) and propidium iodide (PI, 40 µg/mL; Gibco™ Invitrogen™,
Merelbeke, Belgium). Nuclear DNA content was measured using a LSRII flow cytometer and FACS
Diva Software 6.2 (BD Biosciences).
Measurement parameters: The analysis of flow acquisitions was done using FlowJo software 10.4.1.
For the identification of subpopulations of cells in different cell cycle phases, we used forward (FSC)
and side scatter channels (SSC). In the first step of analysis, we removed the debris by performing
an SSC-A versus FSC-A plot. After that, we used a FSC-H versus FSC-A plot to exclude clumps and
doublets. To get rid of debris remains and some apoptotic cells, we used an SSC-H versus SSC-A
plot. In the last step, gated cells were applied to the propidium iodide (PE-A versus PE-W). A final
histogram plot was generated by using Count versus PE-A. The gating of cells was validated in the
control sample, and the same parameters of gating were applied to the other samples. Further analysis
of the identification of the subpopulation of cells in different phases of cell cycles was performed by
a mathematical algorithm, which attempts to fit Gaussian curves to each phase (FlowJo Single Cell
Analysis Software 10).
2.5. Total RNA Isolation, cDNA Synthesis, and Quantitative PCR
Total RNA was isolated using the total RNA Isolation System (InviTrap Spin Cell RNA Mini Kit,
Stratec Molecular, Birkenfeld, Germany) according to the manufacturer’s recommendations. Genomic
DNA was removed by using selective binding to a specific surface of solid material delivered by the
kit producer (Stratec Molecular, Birkenfeld, Germany).
Reverse transcription reactions were performed on 2 µg of total RNA with the PrimeScript RT
Master Mix (Perfect Real Time, Takara, Kusatsu, Shiga, Japan), following the manufacturer’s protocol.
Quantitative Real-Time PCR was performed using an Eco Real-Time PCR System (Illumina,
San Diego, CA, USA). Total reaction volume (10 µL) was mixed using 0.2 nanomoles of forward and
reverse primer, 1 µl of cDNA template (approximately 10 ng), and 5 µL of Takara BioSYBR Green
Master Mix, according to the manufacturer’s recommendations. The amplification conditions for the
Takara BioSYBR Green Master Mix Eco Real Time PCR (Illumina) consisted of an initial step of 30 s
at 95 ◦C, followed by 40 cycles of 5 s at 95 ◦C, and 15 s at 60 ◦C. The following gene-specific primers
have been used: LSD1 f-TGGTAAGAGGTCTGGAGGGA, r-CAGCTTGTCCGTTGGCTTC; CCNA2 f-
ACTGGTGGTCTGTGTTCTGTGA, r-GATGCCAGTCTTACTCATAGCTGAC; CCNB1 f-TGGTGA
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ATGGACACCAAVTC, r-TAGCATGCTTCGATGTGGCA; CCNE1 f-CAGGGAGCGGGATGCG,
r-GGTCACGTTTGCCTTCCTCT; PCNA f-GCTCTTCCCTTACGCAAGTCT, r- AGTCTAGCTGGTTT
CGGCTT; p21 f-CCAGACCAGCATGACAGATTTC, r-GCTTCCTCTTGGAGCAGATCAG; and P53
f-TCTGGGACTTAGTGCCTTTTATGG, r-CAGTCAGAAACTGTCAAATCATCCA. Gene expression
levels were normalized to the level of HPRT1 f-ATGGACAGGACTGAACGTCTT, r-TCC
AGCAGGTCAGCAAAGAA. The delta–delta Ct method was used to determine the relative levels of
mRNA expression between experimental samples and controls.
2.6. Western Blotting
Whole protein cell extract was prepared by using M-PER solution (Thermo Fisher Scientific,
Waltham, MA, USA). First, 20 µg of proteins was separated by SDS-PAGE and transferred to a
polyvinylidene difluoride (PVDF) membrane using a transfer apparatus according to the manufacturer’s
protocols (Bio-Rad, Warsaw, Poland). After incubation with 5% non-fat milk in Tris-buffered saline
with Tween 20 (TBST; 10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 1 h, the membrane was
washed three times for 5 min in TBST at room temperature. Next, the PVDF membrane was probed
with primary antibodies: CAF1A (1:1000, Cell Signaling Technology, Baverly, MA, USA, Cat. 5480);
ph-Chk1(S317) (1:1000, Cell Signaling Technology, Baverly, MA, USA, Cat. 12302); Chk1 (1:1000, Abcam,
ab47444); ph-H2AX(S139) (1:1000, Cell Signaling Technology, Baverly, MA, USA, Cat. 9718); HP1α
(1:1000, Cell Signaling Technology, Beverly, MA, USA, Cat. 2616); and HP1γ (1:1000, Cell Signaling
Technology, Beverly, MA, USA, Cat. 2619); PCNA (1:2000, Cell Signaling Technology, Beverly, MA,
USA, Cat. 2586) was used as a loading control. The incubation was proceeded overnight at 4 ◦C
with agitation. All primary antibodies were diluted in a 3% BSA solution. The next day, membranes
were incubated with horseradish-peroxidase-conjugated secondary antibodies (1:2000, R&D Systems,
Minneapolis, MN, USA, Cat. HAF007, Cat. HAF008) for 1.5 h at room temperature in agitation. The
signal from membrane was visualized using enhanced chemiluminescence (ECL) solution (WESTAR
ETA C 2.0, Cyanagen; Bologna, Italy) and charge-coupled devices (CCD) digital imaging system
Alliance Mini HD4 (UVItec Limited, Cambridge, UK). Values for all analyzed protein were normalized
to the loading control, PCNA.
2.7. Assessing of DNA Damage
Alkaline comet assay. Double DNA strand breaks in nonT/LSD1 KDs HMEC-1 were evaluated
by comet assay and pulsed-field gel electrophoresis. The comet assay was performed under alkaline
conditions essentially according to the procedure of Ahnström et al. [30]. A freshly prepared suspension
of cells in 0.75% low-melting point (LMP) agarose in PBS was spread onto microscope slides pre-coated
with 0.5% NMP agarose. Then, the cells were incubated for 1 h at 4 ◦C in a lysis buffer (2.5 M
NaCl, 100 mM EDTA, 1% Triton X-100, 10 mM Tris, pH 10). After lysis, the slides were placed in an
electrophoresis unit, and the DNA was allowed to unwind for 20 min in the electrophoresis solution
(300 mM NaOH, 1 mM EDTA, pH >13). Electrophoresis was performed at 4 ◦C for 20 min at 0.73 V/cm
(290 mA). Then, the slides were washed in water, drained, stained with DAPI (2 µg/mL), and covered
with coverslips. To eliminate additional DNA damage, all the steps of protocol were performed
under dimmed light or in the dark. The slides were observed at 200×magnification using an Eclipse
fluorescence microscope (Nikon, Tokyo, Japan) attached to a COHU 4910 video camera (Cohu, Inc.,
San Diego, CA, USA) equipped with a UV-1 filter block consisting of an excitation filter (359 nm) and a
barrier filter (461 nm) and image analysis system, Lucia-Comet v. 4.51 (Laboratory Imaging, Prague,
Czech Republic). One hundred images were randomly selected from each sample, and the comet tail
DNA (tail DNA [%]) was measured. Each experiment was repeated three times. The percentage tail
DNA is positively correlated with the level of DNA breakage or/and the number of alkali-labile sites,
and is negatively correlated with the level of DNA cross-links.
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Repair Enzymed Modified Comet Assay
The alkaline comet assay using lesion-specific enzymes: endonuclease-III (Endo III) and
formamidopyrimidine N-glycosylase (Fpg) were used to detect oxidized purines and pyrimidines
(that are generated as a result of oxidative stress-induced DNA damage) [31,32]. The cell-agarose
suspension slides were prepared as described above for the standard comet assay. After lysing, the
slides were washed three times with the enzyme buffer (40 mM HEPES, 100 mM KCl, 0.5 mM EDTA,
and 0.2 mg/mL bovine serum albumin) at room temperature, and were incubated at 37 ◦C for 30 min
with (i) Endo III (1:1000, 30 min), (ii) Fpg (1:1000, 45 min), and (iii) with enzyme buffer (control). Endo
III recognizes oxidized pyrimidines, while Fpg recognizes oxidized purines, specifically 8-oxo-guanine.
The slides were coded and placed in a specifically designed horizontal electrophoresis tank, and the
DNA was allowed to unwind for 20 min in alkaline solution containing 300 mM NaOH and 1 mM
EDTA, pH >13. The DNA was electrophoresed for 30 min at 300 mA and 20 V (0.70 V/cm). Then, the
slides were neutralized with 0.4 M Tris (pH 7.5), stained with SYBR Green I (1:10,000) for 1 h, and
covered with coverslips. As above, 100 images were randomly selected from each sample, and the
comet tail DNA (tail DNA (%)) was measured.
2.8. Statistical Analysis
Statistical analyses were performed by means of STATISTICA 8.0 PL software (StatSoft INC, Tulsa,
Oklahoma). All data were expressed as mean ± SD. Differences between groups were assessed by the
one-way ANOVA, and post hoc analysis by Tukey’s test was performed. A probability p < 0.05 was
considered as statistically significant.
3. Results
3.1. Silencing of LSD1 Results In Abberations of Cell Cycle of Entothelial Cells
The role of LSD1 in the regulation of endothelial cell proliferation was assessed using (i) flow
cytometry for visualization of the cell cycle, (ii) fluorescent microscopy analysis for mitotic index
calculation, and (iii) RT-qPCR for assessing the expression of genes implicated in the regulation of
proliferation, as shown in Figure 1. The knockdown of LSD1 by shRNA (Figure S1) resulted in a
significant modification of cell cycle progression, by increasing the population of cells in G2/M phase
from 20% to 26–30%, as shown in Figure 1B. Due to the silencing of LSD1, we also observed changes in
the expression of major cell cycle drivers such as downregulation of p21 and upregulation of cyclin
A (CCNA2) and cyclin B (CCNB1) Figure 1C (* p < 0.05, ANOVA test). The expression of p53 and
CCND1 was at the control level. Analysis of the mitotic index parameter (MI), which presents the
number of mitotic cells in relation to all cells, confirmed the aberration of cell cycle related with shutting
down LSD1 activity. Specifically, the fluorescent staining of cells (DAPI) showed increased MI in
the population of cells deprived of LSD1 expression (LSD1 KDs HMEC-1) in comparison to control
cells (nonT HMEC-1). Additionally, further microscopic analysis of the M phase of LSD1 KDs/nonT
HMEC-1 revealed an increased number of LSD1 knockdown cells presenting abnormalities in the
division phase, as shown in Figure 1A (grey bars on the figure presents the population of cells with
aberrant M phase in relation to all mitotic cells). The aberrant M-phase cells showed pulverization
(included chromosomal breaks and gaps (≤20), lost and lagging chromosomes, acentric fragments,
segregation defects, and chromosome bridges). The representative visualization of the normal and
aberrant M-cells is presented in Figure S2.
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Figure 1. Effect of pharmacological and transcriptional inhibition of lysine-specific demethylase 1
(LSD1) on cell cycle progression of human microvascular endothelial cells (HMEC-1). (A) The effect of
LSD1 shutdown due to 2-phenylcyclopropylamine (2-PCPA) treatment or shRNA transfection on the
mitotic index, the induction of aberrations in the M phase of cell cycle and apoptosis (MI, a percentage
of mitotic cells in relation to all cells, both interphase and mitotic). The percentages were calculated
based on 3000 cells per repeat; (B,D) Flow cytometry analysis of cell cycle. Cells were stained with
propidium iodide. The obtained histograms were analyzed using FlowJo software 10.4.1. (“A” stands
for the subpopulation of apoptotic cells). Presented histograms are representative of three independent
experiments; (C,E) Gene expression profile of cell cycle regulators in HMEC-1 treated with 100 µM of
2-PCPA (E) or after transcriptional LSD1 silencing by specific shRNA (C). Presented data are average of
three independent experiments. The level of significance was determined at * p < 0.05, ANOVA and
post hoc analysis by Tukey’s test.
To confirm the data obtained on the LSD1 KDs model, we also used 2-PCPA (tranylcypromine
chloride), a pharmacological inhibitor of monoamine oxidases, including lysine-specific demethylase
1 [28,29]. Pharmacological exposure of microvascular endothelial cells with the 2-PCPA (100 µM) for
24 h, 48 h, or 72 h did not the change cell cycle progression assessed by flow cytometry (Figure 1D).
However, we observed slight changes in the expression of genes important for the cell proliferation
process, including p21, cyclin E, and cyclin A (Figure 1E). Similarly to the population of LSD1 KDs
HMEC-1, we found an increase of the MI in the 2-PCPA-treated cells, as shown in Figure 1A (left panel).
3.2. Silencing of LSD1 Activates Checkpoint Kinase 1 (Chk1)
Due to identified abnormalities in the cell cycle after shutting down of the LSD1 demethylase,
including aberration of the M phase and changes in the mRNA expression of cell cycle drivers
(cyclin B, cyclin A, p21), as shown in Figure 1, we next analyzed the activation state of checkpoint
kinase 1 (Chk1), which is critical cycline-dependent kinase (CDK) for G2/M phase transition [33].
Immunofluorescent staining of the phosphorylated form of checkpoint kinase 1 (ph-Chk1(S317)) clearly
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showed an increased level of the activated protein in the knockdown cells, as shown in Figure 2A (black
bars). These data were confirmed by protein blot of whole cellular lysates, as shown in Figure 2E. We
did not find changes between nonT HMEC-1 and LSD1 KDs HMEC-1 in the level of unmodified Chk1,
as shown in Figure 2A (grey bars) and Figure 2E. For better visualization of the immunofluorescence
signal, we used ImageJ software, which allowed presenting the intensity of the fluorescence inside
single nuclei, Figure 2B,C, and featured specific foci (images a6, a7, b6, and b7).
Figure 2. Consequences of LSD1 inhibition/silencing in human microvascular endothelial cells on
checkpoint kinase 1 (Chk1) activation. Immunofluorescent analysis of the Chk1 level (A,B) and the
Chk1 activation (ph-Chk1(S317) level (A,C). Cells were stained with anti-Chk1 or anti-ph-Chk1(S317)
antibodies conjugated with AlexaFluor 488 fluorescent dye. The labeling index was calculated as the
ratio of immunofluorescence-labeled cells to all cells in an HMEC-1 cell population. The intensity
of fluorescence was visualized in ImageJ program (B a6, a7, b6, b7; C a6, a7, b6, b7). The presented
pictures are representative of three independent experiments. (D), (E) Analysis at the protein level
of the expression of Chk1 and ph-Chk1 in (D) pharmacological and (E) transcriptional experimental
models of LSD1 activity inhibition. Scale bars are equal to 10 µm. Statistical significance was analyzed
at * p < 0.05 using ANOVA and post hoc analysis by Tukey’s test.
Furthermore, we observed the activation of Chk1 (ph-Chk1(S317)) in a pharmacological model,
Figure 2A, that corresponds with earlier observations using LSD1 knockdown cells. However, the
activation of Chk1 protein in 2-PCPA treated HMEC-1 was registered only by immunofluorescent
analysis, as shown in Figure 2A,C, not by Western blotting, as shown in Figure 2D. Primary HUVECs
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responded to 100 µM of 2-PCPA by the strong activation of Chk1, Figure S3, comparable to LSD1
knockdown cells.
Based on the obtained results from analysis of cell cycle and Chk1 activation, we concluded that
the silencing of LSD1 results in the G2/M cell cycle arrest.
3.3. LSD1 Alters Chromatin Conformation
As LSD1 activity decides the histone H3 transcription activation/repression marks [24,26], we
performed an analysis of the expression and localization of structural proteins involved in chromatin
organization such as HP1 proteins, chromatin assembly factor 1 (CAF1), and proliferating cell nuclear
antigen (PCNA). All the indicated molecules define a specific architecture for replication foci at
pericentric heterochromatin.
HP1 protein, and its α and γ isoforms, mediate heterochromatin formation and are implicated
in gene silencing by binding to methylated lysines of histone 3 and 4 (H3, H4) i.e., K9, K27, K36,
K79, and K20, which are recognized as the repressive marks, and promoting the recruitment of
other silencing factors, including DNA methyltransferases. The proteins, predominantly localized
in the heterochromatin—except for HP1γ, which is found both in euchromatin and heterochromatin
fractions—also participate in telomeric chromatin organization, and are crucial determinants of
genome stability [34,35]. In our experimental model, we found that the silencing of LSD1 by
shRNA and pharmacological inhibition, reorganizes HP1 to heterochromatic sites and increases HP1α
and HP1γ content by about 20% to 35% when compared to the adequate controls, Figure 3A–C.
Detailed microscopic analysis of images after immunofluorescent staining show significantly larger
HP1α-enriched clusters at the heterochromatin–euchromatin boundaries in LSD1 KD cells and in
cells after 2-PCPA treatment, as shown in Figure 3D and Figure S4. These changes might lead
to an impaired replication of heterochromatic sequences, and we suggest the engagement of the
Chk1-dependent pathway in the LSD1-dependent cell cycle progression. Changes that were registered
by immunofluorescent analysis were not confirmed by Western blotting, as shown in Figure 3H,I.
The differences between the labeling indices of control and inhibitor/shRNA samples were about 20%,
as shown in Figure 3A, and we assume that it might be below the detection sensitivity of the Western
blotting (WB) technique.
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Figure 3. Effect of pharmacological and transcriptional inhibition of lysine-specific demethylase 1
(LSD1) on the ‘topography’ of heterochromatin fraction. Immunofluorescent analysis of HP1 alpha
and gamma localization (A–E) and CAF1A protein (F,G). The labeling index was calculated as the
ratio of immunofluorescence-labeled cells to all cells in an HMEC-1 cell population. Subfigures D
and E show exemplary nuclei from the series “not-treated” (nonT) versus “treated” (LSD1 KDs) for
respectively: HP1 alpha protein and HP1 gamma, and enroll the most characteristic location of specific
foci, labeling heterochromatin regions at the periphery of the interphase nuclei (double red star), which
is usually associated with the nuclear lamina, and perinucleolar heterochromatin (single red star). The
red arrows indicate the unlabeled region (the so-called “hole”) in the location of the nucleoli. The
protein expression of HP1 aplha, HP1 gamma, and CAF1A by Western blotting in cells treated with
100 µM of 2-PCPA (H), and (I) shRNA-transfected HMEC-1. Presented images are representative, and
the data are the average of three independent experiments. Scale bars are equal to 10 µm. * p < 0.05,
ANOVA and post hoc analysis by Tukey’s test.
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Human CAF1 is a nucleosome assembly factor that deposits newly synthesized and acetylated
histones H3 and H4 into nascent chromatin during DNA replication. Similar to HP1γ, CAF1 is targeted
to heterochromatic and euchromatic DNA replication foci fractions. Looking for the effect of LSD1
on dynamics in heterochromatin fraction, we found a significant increase in the amount of CAF1A
(a 150-kDa subunit of the CAF1 complex) in LSD1 KDs, as well as in LSD1 inhibitor-treated cells,
as shown in Figure 3F–I and Figure S5. CAF1A (CAF1-p150) is targeting the CAF1 complex to the
replication fork through direct interaction with proliferating cell nuclear antigen (PCNA). As we found
an increased level of CAF1-p150, we decided to check the PCNA protein level; nevertheless, we did
not observed changes in the cellular content of protein neither in HMEC-1 (Figure 3H,I), nor in the
HUVEC experimental model Figure S5.
In conclusion, the performed studies revealed the potential of LSD1 to affect the higher-order
chromatin structure. The identified changes in the expression and localization of the chromatin
dynamics marks, especially HP1α, suggest that LSD-1 acts as a chromatin relaxing agent.
3.4. Induction of DNA Damage Corresponds with Decreased LSD1 Activity
Due to the significant modifications of the heterochromatin fraction, we assessed potential DNA
damage level using an alkaline comet assay, with and without the addition of the repair enzymes:
endonuclease-III (Endo III) and formamidopyrimidine N-glycosylase (Fpg). Formamidopyrimidine
DNA glycosylase (Fpg) plays a crucial role in the first step of base excision repair, and
removes mainly 7,8-dihydro-8-oxo-2’deoxyguanine (8oxoG) and 2,6-diamino-4-hydroxy-5-N-methyl
formamidopyrimidine from DNA, leading to the generation of apurinic/apyrimidinic sites [31,32].
Endo III (Nth) is a restriction endonuclease that is responsible for the identification of oxidized
pyrimidines and their transformation into DNA strand breaks.
We observed that LSD1 shRNA cells are more susceptible to DNA damage when compared to
nonT control HMEC-1, Figure 4A (no enzyme samples, alkaline unmodified comet assay).
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Figure 4. The tail moment (TM) of oxidatively damaged DNA in the nonT and LSD1 KDs HMEC-1
evaluated by alkaline and modified comet assay using lesion-specific enzyme endo III (endonuclease
III) and FPG (formamidopyrimidine glycosylase) to differentiate DNA double-strand breaks (cells
untreated) from oxidized purines (+ endo III) and pirymidines (+ Fpg). (A), (B) All the values are
expressed as mean ± SD (the number of cells used per repeat, n = 100). The level of significance was
determined at *** p < 0.001 and ** p < 0.01 nonT vs. LSD1 KDs (ANOVA and post hoc analysis by
Tukey’s test).
Next, we induced oxidative stress using 10 µM of hydrogen peroxide, and observed elevated
DNA damage (seven times higher when compared to untreated LSD1 KD cells), as shown in Figure 4B
versus Figure 4A (no enzyme samples). In close agreement with the observation that enzyme-sensitive
sites might be more prone for the strand breaks, we registered significantly higher DNA damage level
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(more than three times) in LSD1 KDs in a modified comet assay (with an Fpg repair enzyme that
identifies oxidized pyrimidines), as compared to alkaline comet assay, as shown in Figure 4A. No
changes in the percent tail DNA in the assay with EndoIII were observed between nonT and LSD1
KDs, as shown in Figure 4B. The level of purine and pyrimidine oxidation after H2O2 treatment was
significantly increased when compared to nonT, as shown in Figure 4B.
To confirm the comet assay result, additionally, we assessed the level of expression of H2AX
Ser139ph and ATRIP, which are the molecules indicated in the literature as markers for DNA damage,
but also indirectly for DNA replication stress. We found that an elevated level of ATRIP in LSD1 KD
cells closely corresponds with the pharmacological inhibition of the enzyme, as shown in Figure 5C–F.
ATRIP and its partner, the master checkpoint kinase ATR, exist as a complex and function together as
the DNA damage response. We observed also an increase in the phosphorylated histone H2AX Ser139
(Figure 5A,B,F), which is a sensitive and specific marker of the DNA damage, especially double-strand
breaks (DBSs) and the subsequent repair of the DNA lesion. Altogether, the obtained data clearly show
how critical the role of LSD1 is in the DNA repair processes.
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Figure 5. Level of DNA damage markers: H2AXS139ph and ATRIP after shutting down LSD1 activity.
(A–D) immunofluorescent localization of the antigens, (E,F) protein level of markers by Western blotting.
Presented images are representative, and the data are the average of three independent experiments.
The labeling index was calculated as the ratio of immunofluorescence-labeled cells to all cells in an
HMEC-1 cell population. Scale bars are equal to 10 µm. * p < 0.05, ANOVA and post hoc analysis by
Tukey’s test.
4. Discussion
Lysine methylation patterns catalyzed by histone methyltransferases/demethylases (HMTs/HDMs)
activity can regulate the cellular processes of diverse substrates such as histone and non-histone
proteins, DNA, RNA, and lipids [36,37]. Through the intense development of pharmacoepigenetics,
we are able to reverse many epigenetic modifications and support the treatment of various diseases,
including cancer [38,39]. A number of studies focus on lysine-specific demethylase 1 (LSD1), because
of its important role in the regulation of cellular metabolism. Increased LSD1 expression has been
found in oral and breast cancers, as well as endometrioid endometrial adenocarcinoma [40–42].
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In the presented study, we examined endothelial cell proliferation, mainly microvascular but
also vein-origin endothelial cells (ECs) via the perspective of LSD1. ECs play a pivotal role in tumor
growth and metastasis due to diapedesis process and their bridge function based on oxygen and
nutrients delivery, which are necessary for tumor development. LSD1 serves as a double-edged sword
by removing methyl groups from K4me1/me2 and/or K9me1/me2 of H3, thus affecting chromatin
conformation and either promoting or repressing the transcription process [2,3]. Using experimental
models of the pharmacological and genetic knockdown of the enzyme, we show a close correspondence
for LSD1 in the regulation of chromatin topography, cell proliferation, and DNA damage/repair
processes in endothelial cells. We found that shRNA silencing of LSD1 results in (i) an increase of the
mitotic index (Figure 1A), and (ii) a block of the cell cycle in the G2/M phase confirmed by flow cytometry
assay and gene expression level of cyclins, cyclin-dependent kinase (CDK) inhibitor p21 (Figure 1B,C),
and Chk1 activation (Figure 2). At the same time, microscopic analysis revealed a significant increase
of aberrant M-phase cells—both 2-PCPA treated and after shRNA LSD-1 silencing—and no change in
the number of apoptotic cells (Figure 1A). Chk1 activation was confirmed by Western blotting, as well
as by the immunofluorescence staining of ph-Chk1 (S317) (Figure 2). These observations are in contrast
to our previous report on G9a histone methyltransferase (G9a HMT), which is an enzyme presenting
a partially adverse effect to LSD1 due to the mono- and dimethylation of H3K9 (H3K9me1/me2),
where we revealed that the silencing of the HMT blocks the cell cycle of endothelial cells in the G0/G1
phase [43]. However, based on the available literature, it appears that LSD1 cell cycle regulation can be
cell-type specific. It was found that in acute lymphoblastic leukemia cell line MOLT-4 and mantle cell
lymphoma JeKo-1, the downregulation of LSD1 by siRNA results in blocking the cell cycle in the G0/G1
phase, an increased expression of p21, and an induction of apoptosis [44]. In the human acute myeloid
leukemia (AML) induced by the MLL-AF9 oncogene (MLL-AF9) mouse model, the abrogation of LSD1
resulted in a heightened rate of apoptosis and impaired leukemogenicity [45]. In addition, analysis
performed on the cells from solid tumors, including prostate cancer cells (PC3 and DU145), showed the
same cell cycle response scheme for LSD1 inhibition. Cells treated with HCI-2509, a reversible LSD1
inhibitor, responded with cell cycle block in the G0/G1 phase [46]. These may suggest that the inhibition
of LSD1 in tumor cells results in G0/G1 cell cycle arrest and apoptosis induction, but recent data on
clear cell renal cell carcinomas (ccRCC) and neuroblastoma cells show that such a generalization is
exaggerated [47,48]. LSD1 inhibition by siRNA knockdown or using the small molecule inhibitor
SP2509 suppressed the growth of ccRCC in vitro and in vivo in G1/S. In addition, a decreased H3K4
demethylation at the CDKN1A gene promoter was found, in association with p21 upregulation [47].
Whereas in neuroblastoma cells (NGP, LAN5 and SK-N-SH), the inhibition of LSD1 with HCI-2509
resulted in G2/M phase cell cycle arrest and an inhibitor concentration-dependent increase in the
methylation of both H3K4me2 and H3K9me2 marks [48]. This is in line with the results presented here
on the endothelial cell model; however, in the analyzed neuroblastoma cells, an increased level of p53
gene expression was observed, which we have not seen in our study.
The observed cell cycle disorder due to LSD1 impaired activity was accompanied by numerous
changes in chromatin remodeling identified by HP1 and CAF1A immunostaining analysis. Mechanisms
contributing to the maintenance of chromatin remodeling in proliferating cells remain poorly
understood. One of the important elements characterizing proliferation machinery is the replication
of heterochromatin occurring in the pericentric regions of chromosomes. In our experimental
model, the immunofluorescence analysis showed that both the pharmacological and transcriptional
silencing of LSD1 results in a significant increase of the heterochromatin protein 1 level, the α and
γ isoforms (Figure 3A–C), and CAF1A protein (Figure 3F,G). Additionally, it was found that the
shRNA downregulation of LSD1 expression is also associated with the perinucleolar heterochromatin
localization of HP-1α and γ (Figure 3D,E, Figure S4). HP-1 proteins are key structural components
of mitotic chromatin that ensure the integrity of chromosomes during cell division [49], and gene
knockdown of HP-1 by RNAi in Drosophila melanogaster Kc cells have been shown to alter cell
cycle progression, with a loss of S and G2/M cell populations and the accumulation of apoptotic
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cells [50]. The presented endothelial cell model confirms the interaction of HP1 with cell cycle
progression also in a LSD1-dependent manner. An increased level of the other mark of heterochromatin
dynamics—CAF1A, which was reported to function in a complex with HP1α and HP1γ proteins, but
also newly synthesized histones H3 and H4 [51,52]—suggests that LSD1 is required for the stable
maintenance of HP1α and HP1γ proteins at sites of pericentric heterochromatin, as it has occurred
for Suv39h and H3K9 methyltransferase [53]. However, the molecular link between heterochromatin
formation and the HP1<>CAF1<>methylation status of H3K4/H3K9 remains still unclear, but slightly
better understandable due to the findings of Yang and co-workers [54]. They have identified in a
fertility screen in female Drosophila melanogaster an ovaries absent gene (ova), which functions in the
stem cell niche, downstream of P-element Induced WImpy testis (Piwi) protein, to support germline
stem cell differentiation. Detailed analysis have revealed that ova links the H3K4 demethylase (dLSD1)
to HP1α for local histone modifications during HP1α-mediated gene silencing, which is required for
ovary development, transposon silencing, and heterochromatin formation [54].
The registered block of the cell cycle in the G2/M phase due to LSD1 silencing accompanied DNA
damage and replication stress identified by comet assay and visualization of ATRIP and H2AX139ph
levels (Figure 4, Figure 5). We also observed significant increases in oxidative DNA damage, twice as
much in LSD1 KDs without oxidative stimulation of cells with hydrogen peroxide (Figure 4A) and
four times more after the oxidant treatment of LSD1 KDs (versus adequate control, nonT; Figure 4B).
These confirms the importance of the LSD1 in the DNA repair [55,56] also in ECs. Except for numerous
irregularities identified by comet assay and Fpg glycosylase/EndoIII endonuclease, also other marks of
DNA damage were significantly increased, i.e., H2AX139ph, confirming the existence of double-strand
breaks (Figure 5A). The literature evidence suggesting that DNA double-strand breaks promote
the transient formation of repressive chromatin [56] enhances our finding on the shRNA shutting
down LSD1 activity. The presented results unambiguously show the importance of LSD1 in the
regulation of the cell cycle, chromatin topography, and DNA repair process in endothelial cells, based
on LSD1-impaired activity models, but also support the multifunctional LSD1 activity profile.
5. Conclusions
Taken together, the data obtained from a genetic inhibition of LSD1 HMEC-1, but also HMEC-1
and HUVECs treated with LSD1 inhibitor to a significant level, revealed a commonality of action
between the chemically induced inhibition of LSD1 and its transcriptional repression, as schematically
summarized in Scheme 1. The observed discrepancy between two models is probably related with
specificity of the studied inhibitor. 2-PCPA beside LSD1 also irreversibly inhibits monoamine oxidases
A and B (MAO-A, MAO-B), which are structurally related to the demethylase. A recent meta-analysis
has shown that the overexpression of LSD1 is associated with worse prognosis in cancer patients [57].
Based on the obtained results, we hypothesize that LSD1 activity could be an important target for
the anticancer therapy, as well as for the treatment of other diseases where endothelial dysfunction is
observed, as our data confirm the dramatic importance of the demethylase in cell cycle progression
and DNA repair, and show that the response of cells to LSD1 inhibition depends on the cell type origin.
Cells 2019, 8, 1212 17 of 21
Scheme 1. Effect of pharmacological and transcriptional inhibition of lysine-specific demethylase 1
(LSD1) on induction of the cell cycle and DNA damage response (DDR) pathway in microvascular
endothelial cells (HMEC-1).
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/10/1212/s1,
Figure S1: Expression level of LSD1 at the protein (upper images, charts; A, B) and transcript level (bottom graphs;
C, D), modified by 2-PCPA treatment and due to shRNA silencing. title, Figure S2: Visualization of cells in different
phases of mitosis (A) and cells undergoing apoptosis (B) after LSD1 shutting down. Figure S3: Effect of treatment
of HUVECs with 2-PCPA on Chk1 activation. Figure S4: Visualisation of changes in the eu/heterochromatin
fraction in HMEC-1 LSD1 KDs based on the HP1 alpha immunofluorescent staining. Figure S5: Effect of 2-PCPA
on heterochromatin fraction remodeling in HUVECs. Figure S6: Effect of 2-PCPA on DNA damage indicators
in HUVECs.
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List of Abbreviations
ATM ataxia telangiectasia mutated serine/threonine kinase
ATR ATM and Rad3-related checkpoint kinase
ATRIP ATR-interacting protein
CAF1 chromatin assembly factor 1
Chk1 checkpoint kinase 1
DOX doxocycline
HMEC-1 human microvascular endothelial cells
HMTs histone methyltransferases
HDMs histone demethylases
HP1 heterochromatin protein 1
LSD1 lysine-specific demethylase 1
PCNA proliferating cell nuclear antigen
phH2AX Ser139 histone H2AX phosphorylated on serine 139
pTRIPZ shRNA
empty lentiviral vector for doxycycline-inducible expression of an short hairpin RNA
together with TurboRFP
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